Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab
- 1 November 2020
- journal article
- letter
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (10) , 3643-3646.e1
Abstract
No abstract availableFunding Information
- AstraZeneca
- GlaxoSmithKline
This publication has 9 references indexed in Scilit:
- Persistence of Sinonasal Disease Despite MepolizumabThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 2019
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine, 2018
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaNew England Journal of Medicine, 2018
- Eosinophilic granulomatosis with polyangiitis in children: Data from the French RespiRare® cohortPediatric Pulmonology, 2018
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisNew England Journal of Medicine, 2017
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): Clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohortArthritis & Rheumatism, 2012
- Formes Frustes of Churg-Strauss SyndromeChest, 1995